Catalyst Pharmaceuticals Partners, Inc. (CPRX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$31.490.00%
Close 2026-07-16 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · CPRX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -16.0% |
| Our one-year growth estimate | diamond | 13.7% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 29.7 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 117 industry peers · Company calendar date is not available
CPRX — M&A activity — Changes in Control of Registrant
Dated 2026-07-16
Changes in Control of Registrant. The disclosures under the Introductory Note, Item 3.01, Item 3.03,
Why it matters: The deal is the main near-term event for CPRX holders. The release said closing was planned for Q3 2026, subject to approvals and other conditions.
Watch forA company filing or press release confirms the merger closed and shares convert to $31.50 cash.
Also watch forA filing or press release says the merger is delayed, approval failed, or the deal ended.
Why it matters: The Phase 1 study found little immune effect at lower doses. Catalyst said this may support use in other chronic rare diseases, but more clinical evidence is needed.
Supportive ifCatalyst or its new owner names a study of vamorolone in another rare disease with long-term inflammation. It gives a start date or trial plan.
Worry ifA company update says it plans no more vamorolone studies in other rare diseases. Or it reports a trial delay or end.
Why it matters: AGAMREE sales rose quickly in Q1, while FYCOMPA sales fell after losing exclusivity. Later reports will show if AGAMREE growth keeps making up for the drop.
Supportive ifA reported quarter shows AGAMREE net product revenue growth above 66.6% year over year.
Worry ifA quarterly report shows AGAMREE net product revenue grew less than 66.6% year over year, or fell year over year.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$16 on $10,000 · ±0.2% | How much price usually moves either way. |
| Bad day | $279 loss on $10,000 · 2.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $1,146 loss on $10,000 · 11.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.